Safety and PK of INM004 in Healthy Volunteers

Phase 1, randomised, single-blind trial of equine immunoglobulin F(ab')2 fragments targeting Shiga toxin in hemolytic uremic syndrome (HUS) (6 arms), sponsored by Inmunova. Primary endpoints: Number of participants with treatment-related adverse events at 4 weeks, Maximum Plasma Concentration at 4 weeks and 3 more. Started Dec 2017; status: completed.